Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|February 7, 2014

Cytovance Biologics Expands GMP Warehouse and Manufacturing Operations

Cytovance Biologics continues to work on the expansion of a manufacturing operations and GMP warehousing facility in Oklahoma.

Cytovance Biologics, a full-service contract manufacturer of mammalian and microbial biologics, continues to work on the expansion of a manufacturing operations and GMP warehousing facility. The multi-million dollar capital investment project is expected to be completed by June 2014.
 
Cytovance selected a construction site two miles north of its current campus in Oklahoma.  The new facility, located at 3500 N. Santa Fe, will house 20,000 ft2 of climate controlled and monitored GMP warehouse space and 10,000 ft2 of space for existing and future manufacturing operations. Initially, this cleanroom space will be used for weighing and dispensing activities.
 
“Our new GMP warehouse will support incoming and outgoing supply-chain activities and provide full segregation between incoming, quarantine, and released materials,” explained Don Wuchterl, senior vice-president of manufacturing operations in a press release.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.